PharmaCyte Biotech, Inc. (PMCB)

NASDAQ: PMCB · Real-Time Price · USD

0.5460

-0.0441 (-7.47%)

At close: Aug 10, 2026, 4:00 PM EDT

0.5512

+0.0052 (0.95%)

After-hours: Aug 10, 2026, 7:31 PM EDT

PharmaCyte Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Net Income	-19.42	30.66	0.33	-4.32	-4.24
Stock-Based Compensation	1.13	0.48	0.67	0.65	0.11
Other Adjustments	15.07	-35.47	-3.46	0.17	-
Changes in Accounts Payable	-0.13	0.01	0.26	-0.24	0.03
Changes in Accrued Expenses	-1.55	1.31	0.19	-0.04	-0
Changes in Other Operating Activities	-0.25	0.04	-0.15	-0.01	-0.02
Operating Cash Flow	-5.15	-2.98	-2.15	-3.79	-4.12
Operating Cash Flow Growth	-	-	-	-	-

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Purchases of Investments	-3	-7	-5	-	-
Proceeds from Sale of Investments	5	-	-	-	-
Investing Cash Flow	2	-7	-5	-	-

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Short-Term Debt Repaid	-	-	-	-	-0.05
Net Short-Term Debt Issued (Repaid)	-	-	-	-	-0.05
Issuance of Common Stock	1.05	-	0	0	87.36
Repurchase of Common Stock	-0.4	-2.54	-28.2	-13.56	-
Net Common Stock Issued (Repurchased)	0.65	-2.54	-28.2	-13.56	87.36
Issuance of Preferred Stock	6.18	-	33.65	-	-
Repurchase of Preferred Stock	-	-22.49	-16.16	-	-
Net Preferred Stock Issued (Repurchased)	6.18	-22.49	17.49	-	-
Preferred Share Dividends Paid	-0.25	-	-	-	-
Financing Cash Flow	6.58	-25.03	-10.71	-13.56	87.31

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Foreign Exchange Rate Adjustments	0	-0	-0	-0.01	0
Net Cash Flow	3.43	-35.01	-17.86	-17.36	83.2

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 30, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022
Free Cash Flow	-5.15	-2.98	-2.15	-3.79	-4.12
Free Cash Flow Growth	-	-	-	-	-
Free Cash Flow Per Share	-0.62	-0.41	-0.22	-7.33	-7.96
Levered Free Cash Flow	-25.13	24.72	-16.94	-4.61	-4.28
Unlevered Free Cash Flow	-8.78	-3.02	-8.22	-6.75	-4.38

SEC Filings: 10-K · 10-Q